CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 987 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00856986
NCT00856986Phase 3Completed
CompareCT.gov

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension

Novo Nordisk A/S·interventional·Posted Mar 6, 2009·Updated Mar 8, 2017

In Brief

A Phase 3 clinical trial evaluating liraglutide, insulin detemir, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 987 participants across 233 sites in 10 countries.

Detailed Summary

This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesBelgium, Canada, France, Germany, Italy, Netherlands, Puerto Rico, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2009
Enrollment StartMar 1, 2009
Primary CompletionApr 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.3 years ago

Interventions

liraglutidedrug

Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.

insulin detemirdrug

Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm

metformindrug

Metformin tablets, at least 1500 mg/day